<DOC>
	<DOCNO>NCT01146119</DOCNO>
	<brief_summary>This multi-center , randomize , two stage , double-blind , placebo-controlled administration study comprise 200 healthy participant .</brief_summary>
	<brief_title>Further Investigation Intramuscular Influenza Vaccine ( Multimeric-001 )</brief_title>
	<detailed_description>This Phase II multi-center , randomize , two stage , double-blind , placebo-controlled study comprise 200 participant . Eligible subject randomize receive one follow administration ( two single IM injection interval 21 day injection Administration A : Prime twice Adjuvanted Multimeric-001 500 mcg - 64 subject . Administration B : PBS ( Placebo ) twice - 32 subject . Administration C : Adjuvanted PBS ( Placebo ) twice - 32 subject . Participants administrations A B immunized 15 % dose commercial seasonal trivalent vaccine 2011 day 81 . Administration D : Adjuvanted Multimeric-001 500 mcg coadministered 15 % TIV dose - 24 subject . Administration E : Adjuvanted Multimeric-001 500 mcg coadministered 50 % TIV dose - 24 subject Administration group F : PBS ( Placebo ) co-administered 50 % TIV dose - 24 subject</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy male female age 18 49 year ( inclusive ) . Subjects provide write informed consent participate study . Subjects able adhere visit schedule protocol requirement available complete study . Haematology , chemistry urinalysis value clinical significance reflect medical condition , accord physician 's judgment , might confound result study pose additional risk subject participation study . Female childbearing age must agree use acceptable method contraception male subject use condom throughout study period ( termination visit ) female partner use effective contraceptive method . Subjects seronegative least one strain include seasonal vaccine influenza 2011 . Known history significant medical disorder , investigator 's judgment , might confound result study pose additional risk subject participation study . Subjects know Guillain Barr√© Syndrome past . Two hospitalization within last year prior screen visit . Known bleed disorder include hemophilia thrombocytopenia , treatment anticoagulant therapy ( risk bleed intramuscular injection ) . Immunocompromised patient receive concomitant immunosuppressive therapy ; immune modulating drug include chronic steroid treatment . Subjects immunized antiinfluenza vaccine infect influenza virus within eight month prior screen visit . Administration vaccine 30 day screen visit . Known hypersensitivity previous influenza vaccination . Use influenza antiviral medication within 4 week vaccination . Known hypersensitivity and/or allergy drug vaccine . Known hypersensitivity egg protein ( egg egg product ) , chicken protein , vaccine component . Known history drug alcohol abuse . Any clinically significant abnormality upon physical examination clinical laboratory test screen visit , accord physician 's judgment , might confound result study pose additional risk subject participation study . Increased liver enzymes 2.5 time upper reference level . Positive serology HIV , HCV antibody HBsAg . Any acute medical situation ( e.g . acute infection , ongoing flu symptom ) without fever within 48 hour vaccination , consider significance Principal Investigator . Pregnant lactate woman entry study unwilling agree continue use acceptable method contraception two month completion study ( applicable ) . Positive blood pregnancy test screening . Subjects participate clinical study within 30 day prior study entry Subjects noncooperative unwilling sign consent form .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>HAI</keyword>
	<keyword>Influenza</keyword>
	<keyword>prime</keyword>
	<keyword>boost</keyword>
	<keyword>immune response</keyword>
	<keyword>seroconversion</keyword>
	<keyword>universal</keyword>
	<keyword>vaccine</keyword>
</DOC>